74
Participants
Start Date
March 31, 2009
Primary Completion Date
September 30, 2009
Study Completion Date
February 28, 2011
Atacicept 25 mg
Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Atacicept 75 mg
Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Atacicept 150 mg
Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Atacicept 150 mg
Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Research Site, Phoenix
Research Site, Northbrook
Research Site, East Lansing
Research Site, Cleveland
Research Site, Philadelphia
Research Site, Nashville
Research Site, Box Hill VIC
Research Site, Fitzroy
Research Site, New Lambton
Research Site, Woodville
Research Site, Diepenbeek
Research Site, Sijsele
Research Site, Calgary
Research Site, Ottawa
Research Site, Brno
Research Site, Hradec Králové
Research Site, Caen
Research Site, Saint-Herblain
Research Site, Bochum
Research Site, Düsseldorf
Research Site, Beirut
Research Site, Kaunas
Research Site, Breda
Research Site, Nieuwegein
Research Site, Rotterdam
Research Site, Winston Salem
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Saint Petersburg
Research Site, Samara
Research Site, Vladimir
Research Site, Yaroslavl
Research Site, Yekaterinburg
Research Site, Barcelona
Research Site, Madrid
Research Site, Málaga
Research Site, Stockholm
Research Site, Basel
Research Site, Innsbruck
Research Site, Zurich
Research Site, Kharkiv
Research Site, Kyiv
Research Site, Odesa
Research Site, Uzhhorod
Research Site, London
Research Site, Sheffield
Research Site, Stoke-on-Trent
Lead Sponsor
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono
INDUSTRY